XTX Topco Ltd Makes New Investment in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

XTX Topco Ltd bought a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 83,286 shares of the company’s stock, valued at approximately $625,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. DekaBank Deutsche Girozentrale acquired a new stake in Kyverna Therapeutics during the 1st quarter worth about $181,000. Teachers Retirement System of The State of Kentucky acquired a new stake in Kyverna Therapeutics during the first quarter worth approximately $313,000. Federated Hermes Inc. bought a new stake in Kyverna Therapeutics in the second quarter worth approximately $120,000. Rhumbline Advisers acquired a new position in Kyverna Therapeutics in the second quarter valued at approximately $150,000. Finally, Sofinnova Investments Inc. boosted its holdings in shares of Kyverna Therapeutics by 378.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 47,850 shares of the company’s stock worth $359,000 after buying an additional 37,850 shares in the last quarter. Institutional investors and hedge funds own 18.08% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. HC Wainwright reiterated a “neutral” rating and issued a $7.00 price objective on shares of Kyverna Therapeutics in a research note on Thursday, September 19th. JPMorgan Chase & Co. dropped their price objective on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $34.40.

Kyverna Therapeutics Stock Performance

Shares of KYTX stock opened at $5.85 on Tuesday. The firm has a fifty day simple moving average of $7.82 and a two-hundred day simple moving average of $13.35. Kyverna Therapeutics, Inc. has a 12 month low of $5.72 and a 12 month high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Monday, August 12th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.03. As a group, analysts predict that Kyverna Therapeutics, Inc. will post -3.38 earnings per share for the current year.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.